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ORIGINAL RESEARCH
Cardiac Conduction Disorders as Markers 
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Type 1
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Toshiaki Takahashi, MD, PhD; Hiroto Takada, MD, PhD; Satoshi Kuru, MD; Chizu Wada, MD, PhD;  
Mikiya Suzuki, MD; Shugo Suwazono, MD, PhD; Shingo Sasaki, MD, PhD; Ken Okumura, MD, PhD;  
Minoru Horie, MD, PhD; Masanori P. Takahashi, MD, PhD; Tsuyoshi Matumura, MD, PhD
BACKGROUND: Myotonic dystrophy type 1 involves cardiac conduction disorders. Cardiac conduction disease can cause fatal 
arrhythmias or sudden death in patients with myotonic dystrophy type 1.
METHODS AND RESULTS: This study enrolled 506 patients with myotonic dystrophy type 1 (aged ≥15  years; >50 cytosine-
thymine-guanine repeats) and was treated in 9 Japanese hospitals for neuromuscular diseases from January 2006 to August 
2016. We investigated genetic and clinical backgrounds including health care, activities of daily living, dietary intake, cardiac 
involvement, and respiratory involvement during follow-up. The cause of death or the occurrence of composite cardiac events 
(ie, ventricular arrhythmias, advanced atrioventricular blocks, and device implantations) were evaluated as significant out-
comes. During a median follow-up period of 87 months (Q1–Q3, 37–138 months), 71 patients expired. In the univariate analy-
sis, pacemaker implantations (hazard ratio [HR], 4.35; 95% CI, 1.22–15.50) were associated with sudden death. In contrast, 
PQ interval ≥240 ms, QRS duration ≥120 ms, nutrition, or respiratory failure were not associated with the incidence of sudden 
death. The multivariable analysis revealed that a PQ interval ≥240 ms (HR, 2.79; 95% CI, 1.9–7.19, P<0.05) or QRS duration 
≥120 ms (HR, 9.41; 95% CI, 2.62–33.77, P < 0.01) were independent factors associated with a higher occurrence of cardiac 
events than those observed with a PQ interval <240 ms or QRS duration <120 ms; these cardiac conduction parameters were 
not related to sudden death.
CONCLUSIONS: Cardiac conduction disorders are independent markers associated with cardiac events. Further investigation 
on the prediction of occurrence of sudden death is warranted.
Key Words: conduction disturbance ■ myotonic dystrophy ■ sudden death ■ ventricular tachycardia
Myotonic dystrophy is a neuromuscular disease of autosomal dominant inheritance character-ized by multi-organ involvements. Cardiac con-
duction diseases are considered major involvements 
in myotonic dystrophy type 1 (DM1). This event has 
been associated with sudden death, which occurs 
commonly in patients with DM1.1,2 Recent research 
showed that the optimization of medical and device 
therapies recovered the cardiac function and reduced 
the number of outpatient clinic visits or cardiac-related 
hospitalizations in patients with DM1.2 Notably, implan-
tation of a pacemaker device following an evaluation 
through electrophysiological study has been reported 
to prevent sudden death in patients with DM1.3 On 
the other hand, it remains unclear whether only car-
diac conduction diseases increase the risk of sudden 
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death in DM1.4-6 The objective of this multicenter study 
conducted in Japan was to determine whether car-
diac conduction disorders are associated with cardiac 
events and sudden death in patients with DM1.
METHODS
The institutional review board of each participating 
center approved this retrospective study. This study 
was publicly declared and written informed consent 
was waived because of its retrospective design. None 
of the patients refused to participate in the study. The 
data supporting the findings of this study are avail-
able from the corresponding author upon reasonable 
request.
Subjects
The present study enrolled patients who had under-
gone genetic testing, with multivariable data including 
cardiac and respiratory involvement, activities of daily 
living (ADL), dietary intake, and basic clinical informa-
tion. A total of 528 patients with DM1 with a CTG length 
>50 repeats treated in 9 Japanese centers specializing 
in neuromuscular diseases from January 1, 2006 to 
August 31, 2016 were recruited. Twenty-two patients 
were excluded from this study: 20 patients with DM1 
were aged <15  years, 1 patient was also diagnosed 
with Charcot–Marie–Tooth disease, and 1 patient was 
registered twice. Finally, 506 patients with DM1 (249 
men and 257 women) with a median age of 40 years 
(Q1–Q3, 32–49 years) at the initiation of the follow-up 
were studied (Table 1). These patients with DM1 were 
retrospectively analyzed during a median follow-up pe-
riod of 87 months (Q1–Q3, 37–138 months).
Clinical Characteristics at Baseline
This study was approved and performed under the 
guidelines of the institutional ethics committee at each 
participating center. We collected genetic and clinical 
information (Table 2), and a total of 4979 ECGs were 
analyzed. We measured the following ECG param-
eters: RR interval, PQ interval, QRS duration, QT inter-
val, and JT interval with a speed of 25 mm/s and per 
each setting in the leads II and III, aVF, or V5 (if lead II 
was unavailable). ECGs with pacing rhythm were ex-
cluded from the analysis. Ventricular tachycardia was 
defined as collapsed circulation with documented ECG 
>30  s. Cardiac events were defined as documented 
ventricular tachycardia, conduction disorders including 
advanced atrioventricular blocks, sick sinus syndrome, 
or device implantations.
Sudden death was defined as death occurring sud-
denly and unexpectedly in patients who were stable 
CLINICAL PERSPECTIVE
What Is New?
• This retrospective study, which enrolled 506 pa-
tients with myotonic dystrophy type 1 in Japan, 
showed that cardiac conduction disorders are 
independent markers associated with cardiac 
events but not sudden death.
• The incidence of sudden death was lower in 
Japan despite the lower frequency of pace-
maker implantations versus France or the 
United States.
• The clinical factors associated with the occur-
rence of sudden death in patients with myotonic 
dystrophy type 1 remain unclear.
What Are the Clinical Implications?
• Treatment for conduction disorders alone fails 
to prevent sudden death attributable to myo-
tonic dystrophy type 1.
• Intervention against respiratory disease may be 
the most crucial target for the prevention of sud-
den death in patients with myotonic dystrophy.
Nonstandard Abbreviations and Acronyms
ADL activities of daily living
DM1 myotonic dystrophy type 1
HR hazard ratio
Table 1. Baseline Characteristics of Participants
Patients, n 506
No. of CTG repeats 830 (499–1331)
Age, y 40 (32–49)




Bed rest, % 2.4
Nutrition support, % 3.8





Pacemaker Implantation, % 0.6
ECG
Heart rate, bpm 70.1 (60.3–79.5)
Prolonged PQ interval, % 11.8
Wide QRS duration, % 20.3
Prolonged QTc interval, % 33.0
Values are expressed as the median (Q1–Q3) for continuous variables and 
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before the event.1 Witnessed deaths were classified as 
sudden only if death occurred within 1 hour after the 
onset of new symptoms. Unwitnessed deaths were 
considered sudden if the patient was alive and stable 
within 24 hours before the event. In patients in whom 
the temporal sequence was consistent with sudden 
death, but a specific cause of death other than ar-
rhythmia was confirmed, the death was classified as 
non-sudden.
Statistical Analysis
We used demographics, clinical characteristics (ADL 
categories [being bedridden or not], nutrition cat-
egories [receiving nutrition support or not], oxygen 
therapy [yes or no], tracheotomy [yes or no]), history 
of diabetes mellitus or arrhythmia (atrial fibrillation 
and ventricular tachycardia), pacemaker implanta-
tion, and ECG parameters (heart rate, prolonged PQ 
interval [defined as PQ interval ≥240 ms], wide QRS 
duration [defined as QRS duration QRS ≥120  ms], 
and prolonged QTc interval [defined as ≥440 ms for 
men and ≥460 ms for women]). The relative risk of 
death from any causes and respiratory failure, sud-
den death, and cardiac events, including ventricular 
tachyarrhythmia, conduction disease, and device 
implantation, were estimated for individual covariates 
using the Cox proportional-hazards model. Cardiac 
events were analyzed in the subset of patients with-
out a history of sustained ventricular tachycardia and 
pacemaker implantation. Given the low number of 
deaths and events, the multivariable models were 
limited to variables emerging with a P<0.20 or P<0.10 
from the univariate Cox potential-hazards model.7 
The proportionality of hazard assumption for all out-
comes was statistically assessed on the basis of the 
Schoenfeld residuals; there was found no violation 
of the hazard assumption’s proportionality. The fol-
low-up time was the interval from the baseline to the 
most recent assessment, death, or diagnosis of the 
initial cardiac events. Patients for whom data on out-
comes were not available were censored at the most 
recent evaluation. Changes in characteristics during 
the follow-up were incorporated as time-dependent 
covariates. The analyses were performed using the 
STATA 14.0 software (StataCorp LP, College Station, 
TX, USA). Two-tailed P<0.05 denoted statistical 
significance.
RESULTS
DM1 With Sudden Death
The causes of 69 deaths – excluding those of un-
known cause (n=2) – were classified as sudden 
(26%, n=18) or non-sudden (74%, n=51). Non-sudden 
deaths were subclassified into those related to pro-
gressive neuromuscular respiratory failure (38%, 
n=26) and other deaths (36%, n=25). Progressive 
neuromuscular respiratory failure was defined as 
death resulting from respiratory dysfunction related 
to myotonic dystrophy. Among the 18 sudden deaths, 
5 and 13 were witnessed and unwitnessed during 
the follow-up period, respectively. The median age 
at the time of sudden death was 58 years (Q1–Q3, 
51–63 years), and 10 of those patients were women. 
Based on the ECG finding or other clinical informa-
tion, sudden death was unexpected in 14 cases. The 
remaining 4 cases had sudden death associated 
with cardiogenic shock (n=1), device replacement 
(n=1), and without information at the time of sudden 
death (n=2).
Figure 1 shows the univariate analysis between 
the characteristics of the patients and death from any 
causes, respiratory failure, or sudden death. The age of 
patients was associated with any causes of death, and 
the hazard ratio (HR) of sudden death was 1.08 (95% CI, 
1.03–1.13) with age. Pacemaker implantation was signifi-
cantly related to the occurrence of sudden death with 
an HR of 4.35 (95% CI, 1.22–15.50). In contrast, ECG 
markers including the prolongation of PQ interval or 
QRS duration were not associated with the occurrence 
Table 2. Clinical Characteristics of Recruited Participants






















Respiratory support (NPPV or ventilator)
Medical treatment
ADL indicates activities of daily living; BNP, B-type natriuretic peptide; and 
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of sudden death. The conditions of patients, including 
ADL, nutrition, and respiratory support were also not 
related to sudden death but death of any causes with 
HR of 1.96 (95% CI, 1.53–2.51), 2.92 (95% CI, 1.78–4.77) 
and 3.65 (95% CI, 2.26–5.91) or respiratory failure with 
HR of 2.09 (95% CI, 1.39–3.12), 3.94 (95% CI, 1.76–8.85) 
and 7.49 (95% CI, 3.22–17.41), respectively.
DM1 With Cardiac Events
Figure 2 shows the univariate analysis between the 
characteristics of the patients and cardiac events 
(ie, documented ventricular tachycardia, conduction 
diseases, or device implantation). Cardiac events 
occurred frequently in older patients with (HR, 1.06; 
Figure 1. Univariate analysis between the characteristics of the patients and death from any 
causes, respiratory failure, and sudden death.
Univariate relative risks and P values were calculated using the Cox proportional-hazards analysis for time 
to death from any cause, death from progressive neuromuscular respiratory failure, and sudden death. 
All covariates, except for age and sex, were time-dependent. Hazard ratio per 1-log unit higher in number 
of CTG repeats. Hazard ratio per 10 bpm higher in heart rate. AF indicates atrial fibrillation; HR indicates 
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Figure 2. Univariate analysis between the characteristics of the patients and cardiac events.
Univariate relative risks and Pvalues were calculated using the Cox proportional-hazards analysis for time 
to incidence of ventricular tachyarrhythmia, conduction disease, device implantation, and cardiac events. 
All covariates, except for age and sex, were time-dependent. Hazard ratio per 1-log unit higher in number 
of CTG repeats. Hazard ratio per 10 bpm increase in heart rate. AF indicates atrial fibrillation; HR, hazard 
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95% CI, 1.02–1.10). Worsened ADL was significantly 
associated with the incidence of cardiac events and 
patients with DM1 at bed rest had a higher frequency 
of cardiac events with (HR, 1.79; 95% CI, 1.15–2.79) 
than those with well-conditioned ADL. This result 
was unlike the relationship between sudden death 
and ADL. Nutrition support was also associated 
with a significant incidence of cardiac events (HR, 
3; 95% CI, 1.29–6.94). Notably, cardiac conduc-
tion disorders such as PR prolongation or increased 
QRS duration were significantly associated with the 
occurrence of all cardiac events (HR, 4.52; 95% CI, 
1.99–10.27 and HR, 9.91; 95% CI, 3.38–29.08, re-
spectively) and each category of composite cardiac 
events. Higher heart rates were also associated with 
a lower incidence of cardiac events (HR, 0.58; 95% 
CI, 0.43–0.78).
Multivariable Association Between the 
Characteristics of Patients With DM1 and 
Outcomes
Figure 3 shows the multivariable analysis between 
the characteristics of patients with DM1 and out-
comes including death from any causes, death from 
respiratory failure, sudden death, or cardiac events. 
Age was a significant factor associated with the oc-
currence of sudden death (HR, 1.09; 95% CI, 1.03–
1.14) and any causes of death (HR, 1.09; 95% CI, 
1.06–1.12). In contrast, bed rest, nutrition support, or 
oxygen administration corresponding to ADL indica-
tors, nutrition, or respiratory failure were not associ-
ated with the incidence of sudden death or cardiac 
events. Cardiac involvements including ventricular 
tachycardia, pacemaker implantation, or increased 
QRS duration did not exhibit a significant association 
with the occurrence of sudden death; patients with 
DM1 with a PQ interval ≥240  ms or QRS duration 
≥120 ms were linked to a higher incidence of cardiac 
events than those with a PQ interval <240 ms or QRS 
duration <120  ms (HRs of 2.79 [95% CI, 1.09–7.19] 
and 9.41 [95% CI, 2.62–33.77], respectively). As 
shown in Figure S1, these findings were also ob-
served when the multivariable analysis was limited to 
variables emerging with a P<0.10.
DISCUSSION
This multicenter study examined 506 patients with 
DM1 in Japan and revealed that cardiac conduction 
disorders were independent markers associated with 
the incidence of cardiac events. This is consistent with 
reports from the United States1 and France7. On the in-
cidence of sudden death in patients with DM1, the pre-
sent analysis revealed inconsistent results compared 
with the previous reports.1 This finding suggests that 
pacemaker implantation may prevent sudden death in 
patients with DM1 involved cardiac conduction disor-
ders. At the same time, we need to identify another 
reason for the sudden death which occurred patients 
without cardiac involvements including cardiac con-
duction disorder or pacemaker implantation.
DM1 is a neuromuscular disease with multi-organ 
involvement, which is caused by an expansion of CTG 
repeats in the 3’ untranslated region of the dystrophia 
myotonica protein kinase gene. The number of CTG 
repeats has been associated with the age at onset8 
and incidence9,10 of cardiac involvement. Patients with 
DM1 experience conduction disturbances (ie, atrio-
ventricular block, bundle branch blocks, or sick sinus 
syndrome) and tachyarrhythmias (ie, atrial fibrillation or 
ventricular tachycardias) as major cardiac events.11,12 
ECG markers such as non-sinus rhythm, PR inter-
val ≥240  ms, QRS duration ≥120  ms, or second- or 
third-degree atrioventricular block, should be eval-
uated daily, as these ECG conditions correspond to 
cardiac arrhythmias (including fatal ventricular arrhyth-
mias or atrial fibrillation) and sudden death. Moreover, 
invasive electrophysiological study should be consid-
ered for those patients to determine the need for the 
placement of a pacemaker or implantable cardioverter 
defibrillator.13 A prospective electrophysiological study 
performed by Wahbi et al.3 reported that an intraven-
tricular conduction time (His-Ventricle interval) >70 ms 
should be considered an indication for pacemaker im-
plantation in patients with DM1. Thus, the His-Ventricle 
interval is critical for the prognosis, and pacemaker 
implantation after electrophysiological study may be 
useful for the primary prevention of sudden death in 
patients with DM1. Sudden death is commonly ob-
served in such patients, and it was noted that those 
who need to undergo pacemaker implantations are at 
a high risk of sudden death. The treatments strategy 
for cardiac involvements is essential for the prevention 
of sudden death in patients with DM1.
Cardiac conduction disorders have been associ-
ated with sudden death, and cardiac pacemaker ther-
apy may prevent sudden death in patients with DM1.1,3 
More recently, a multivariable analysis conducted by 
Wahbi et al.3 reported that only left bundle branch block 
Figure 3. Multivariable analysis between the characteristics of patients and outcomes.
Multivariable relative risks and P values were calculated using the Cox proportional-hazards model for time to death from any cause, 
death from progressive neuromuscular respiratory failure, sudden death, and incidence of cardiac events. The multivariable models 
were limited to variables emerging with a P<0.2 from the univariate analysis. All covariates, except for age, were time-dependent. 
Hazard ratio per 10 bpm increase in heart rate. Hazard ratio per year of age. AF indicates atrial fibrillation; HR, hazard ratio; NA, not 
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was associated with sudden death. They concluded 
that a higher ratio of pacemaker implantations com-
pared with that calculated in a previous study (19.7% 
versus 10%, respectively) may prevent sudden death in 
patients with DM1.1 As shown Figure 4, the frequency 
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(17 of 506 patients). However, the multivariable statis-
tical analysis did not demonstrate a positive correla-
tion between sudden death and cardiac conduction 
disorders. Furthermore, the majority of the last ECGs 
before sudden death in each patient with DM1 failed to 
reveal a conduction problem, with most QRS durations 
being within normal limits. We noted that the cause of 
sudden death in patients with DM1 may be attributed 
to various factors (Figure 5). Especially sudden death 
in Japanese patients with DM1 had been unexpect-
edly caused by cardiac conduction disturbance and 
other involvements. Cardiac conduction disturbance 
among patients with DM1 who experienced sudden 
death was observed less commonly in Japan despite 
the lower frequency of pacemaker implantation com-
pared with that reported in patients from the United 
States or France. Although we also investigated the 
underlying mechanism for sudden death through the 
evaluation of multiple clinical factors except for cardiac 
involvements, we were unable to reach a convincing 
conclusion.
The management of cardiac conduction diseases 
as a major cause of sudden death in DM1 is of crucial 
importance. Implantable cardioverter defibrillator or 
cardiac resynchronization therapy for the treatment for 
bradycardia and ventricular tachyarrhythmias, would 
benefit the prevention of sudden death in patients with 
DM1. Cardiac resynchronization therapy has been con-
sidered an option in patients with DM with both left ven-
tricular dysfunction and left bundle branch block.14 On 
the other hand, it is established that we may be unable 
to easily predict the risk of sudden death in patients 
with DM1 because of the complexity of treatment or 
healthcare resources. Notably, it is insufficient to man-
age cardiac conduction diseases without address-
ing the multi-organ involvement in DM1. Respiratory 
muscle gradually weakens with the reduction of lung 
volume in DM1, and some DM1 cases will occasion-
ally require non-invasive mechanical ventilation for the 
treatment of respiratory failure. Nocturnal sleep apnea 
syndrome is frequently observed and can affect the 
prognosis of DM1. It currently remains unclear whether 
mechanical support may improve the prognosis of 
DM1. Nevertheless, respiratory disease increases the 
complexity related to the cause of sudden death in pa-
tients with DM1, and may be the most critical target for 
the prevention of sudden death in this setting.4
CONCLUSIONS
Sudden death is a critical concern in the management 
of DM1 and has been associated with cardiac con-
duction diseases. Appropriate care during hospitaliza-
tion may assist in resuscitating patients with DM1 from 
aborted sudden cardiac death because of ventricular 
tachycardias or critical bradyarrhythmias. In our retro-
spective analysis, cardiac conduction disorders were 
associated with documented cardiac events, but not 
sudden death. This finding emphasizes that physicians 
should consider the risk of sudden death even in pa-
tients with DM1 without conduction disorders.
Figure 4. Patients’ outcomes in each cohort: the United 
States, France, and Japan.
Although the frequency of pacemaker implantations was less 
common in Japan (3.3%) than the United States (10%) and 
France (20%), the rate of sudden death was not lower in Japan 
compared with those observed in the 2 other countries. The data 
for the United States and France were obtained from the New 








All death Sudden death Pacemaker(%)
Figure 5. A schema associated with the etiology of sudden 
death in DM1.
AV, indicates atrioventricular; DM1, myotonic dystrophy type 1; 
SSS, sick sinus syndrome; and VT, ventricular fibrillation.
Sudden death in DM1
Conduction diseases
SSS, AV block, VT






 http://ahajournals.org by on Septem
ber 18, 2020
J Am Heart Assoc. 2020;9:e015709. DOI: 10.1161/JAHA.119.015709 9
Itoh et al Sudden Death in Myotonic Dystrophy Type 1
ARTICLE INFORMATION
Received January 1, 2020; accepted July 13, 2020.
Affiliations
From the Department of Cardiovascular Medicine, Shiga University of 
Medical Science, Otsu (H.I., M.H.); Division of Patient Safety, Hiroshima 
University Hospital, Hiroshima (H.I.); Department of Public Health, Okayama 
University Graduate School of Medicine, Dentistry and Pharmaceutical 
Sciences, Okayama (T.H.); Department of Neurology, National Hospital 
Organization Higashisaitama National Hospital, Saitama (T.T., M.S.); 
Department of Cardiology, National Center Hospital, National Center of 
Neurology and Psychiatry, Tokyo (K.S.); Department of Neurology, National 
Hospital Organization Sendai-Nishitaga Hospital, Sendai (T.T.); Department 
of Neurology, National Hospital Organization Aomori National Hospital, 
Aomori (H.T.); Department of Neurology, National Hospital Organization 
Suzuka National Hospital, Suzuka (S.K.); Department of Neurology, 
National Hospital Organization Akita National Hospital, Akita (C.W.); Division 
of Neurology and Center for Clinical Neuroscience, National Hospital 
Organization Okinawa National Hospital, Ginowan (S.S.); Department 
of Advanced Management of Cardiac Arrhythmias, Hirosaki University 
Graduate School of Medicine, Hirosaki (S.S.); Advanced Arrhythmia 
Therapeutic Branch, Division of Cardiology, Saiseikai Kumamoto Hospital 
Cardiovascular Center, Kumamoto (K.O.); Center for Epidemiologic 
Research in Asia and Department of Cardiology, Shiga University of Medical 
Science, Otsu (M.H.); Department of Functional Diagnostic Science, Osaka 
University Graduate School of Medicine, Suita (M.P.T.);  and Department of 
Neurology, National Hospital Organization Osaka Toneyama Medical Center 
5-1-1, Toyonaka, Japan (T.M.).
Sources of Funding
Dr Masanori Takahashi received a research grant from the Japan Agency 






 1. Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, 
Pourmand R, Otten RF, Bhakta D, Nair GV, et al. Electrocardiographic 
abnormalities and sudden death in myotonic dystrophy type 1. N Engl J 
Med. 2008;358:2688–2697.
 2. Nikhanj A, Yogasundaram H, Miskew Nichols B, Richman-Eisenstat 
J, Phan C, Bakal JA, Siddiqi ZA, Oudit GY. Cardiac intervention im-
proves heart disease and clinical outcomes in patients with muscular 
dystrophy in a multidisciplinary care setting. J Am Heart Assoc. 2020;9: 
e014004. DOI: 10.1161/JAHA.119.014004.
 3. Wahbi K, Meune C, Porcher R, Bécane HM, Lazarus A, Laforêt 
P, Stojkovic T, Béhin A, Radvanyi-Hoffmann H, Eymard B, et al. 
Electrophysiological study with prophylactic pacing and survival in 
adults with myotonic dystrophy and conduction system disease. JAMA. 
2012;307:1292–1301.
 4. Dello Russo A, Pace M, Bellocci F. Sudden death in myotonic dystro-
phy. N Engl J Med. 2008;359:1626.
 5. Petri H, Vissing J, Witting N, Bundgaard H, Køber L. Cardiac manifesta-
tions of myotonic dystrophy type 1. Int J Cardiol. 2012;160:82–88.
 6. Merino JL, Carmona JR, Fernández-Lozano I, Peinado R, Basterra 
N, Sobrino JA. Mechanisms of sustained ventricular tachycardia in 
myotonic dystrophy: implications for catheter ablation. Circulation. 
1998;98:541–546.
 7. Wahbi K, Babuty D, Probst V, Wissocque L, Labombarda F, Porcher R, 
Bécane HM, Lazarus A, Béhin A, Laforêt P, et al. Incidence and predic-
tors of sudden death, major conduction defects and sustained ventric-
ular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. 
Eur Heart J. 2017;38:751–758.
 8. Merlevede K, Vermander D, Theys P, Legius E, Ector H, Robberecht 
W. Cardiac involvement and CTG expansion in myotonic dystrophy. 
J Neurol. 2002;249:693–698.
 9. Melacini P, Villanova C, Menegazzo E, Novelli G, Danieli G, Rizzoli G, 
Fasoli G, Angelini C, Buja G, Miorelli M, et al. Correlation between car-
diac involvement and CTG trinucleotide repeat length in myotonic dys-
trophy. J Am Coll Cardiol. 1995;25:239–245.
 10. Chong-Nguyen C, Wahbi K, Algalarrondo V, Bécane HM, Radvanyi-
Hoffman H, Arnaud P, Furling D, Lazarus A, Bassez G, Béhin A, et al. 
Association between mutation size and cardiac involvement in myotonic 
dystrophy type 1: an analysis of the DM1-heart registry. Circ Cardiovasc 
Genet. 2017;10:e001526. 10.1161/CIRCG ENETI CS.116.001526.
 11. Nikhanj A, Sivakumaran S., Nikhanj A, Sivakumaran S, Miskew-
Nichols B, Siddiqi ZA, Oudit GY. Ventricular tachycardia in patients 
with type 1 myotonic dystrophy: a case series. Eur Heart J Case Rep. 
2019;3:ytz095.
 12. NcNally EM, Mann DL, Pinto Y, Bhakta D, Tomaselli G, Nazarian S, Groh 
WJ, Tamura T, Duboc D, Itoh H, et al. Clinical care recommendations 
for cardiologists treating adults with myotonic dystrophy. J Am Heart 
Assoc. 2020;9:e014006. DOI: 10.1161/JAHA.119.014006.
 13. Feingold B, Mahle WT, Auerbach S, Clemens P, Domenighetti 
AA, Jefferies JL, Judge DP, Lal AK, Markham LW, Parks WJ. et al. 
Management of cardiac involvement associated with neuromuscu-
lar diseases: A scientific statement from the american heart associa-
tion. Circulation. 2017;136:e200–e231. DOI: 10.1161/CIR.00000 00000 
000526.
 14. Nikhanj A, Sivakumaran S, Yogasundaram H, Becher H, Kimber 
S, Siddiqi ZA, Oudit GY. Comparison of usefulness of cardiac re-
synchronization therapy in patients with type 1 myotonic dystro-


















 http://ahajournals.org by on Septem
ber 18, 2020
Figure S1. Multivariate analysis between the characteristics of patients and outcomes.  
 
Multivariate relative risks and P-values were calculated using the Cox proportional-hazards 
model for time to death from any cause, death from progressive neuromuscular respiratory 
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variables emerging with a P<0.1 from the univariate analysis. All covariates, except for age, 
were time-dependent. P-values: *<0.05; †<0.01; ‡<0.001. §Hazard ratio per 1-year older. ¶Hazard 
ratio per 10 bpm increase in heart rate. HR, hazard ratio; NA, not available; AF, atrial 
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